The reporter learned that there are 187 original innovative drugs currently in clinical research in China, of which 2/3 drugs are in Phase I clinical studies, and drugs in Phase II clinical studies and Phase III clinical studies account for 19% and 22%, respectively.
According to the above-mentioned IMS sources, among the 187 original innovative drugs, 70 drugs have compound patent protection in China, compared with 23 U.S. patents and 16 European patents.
In fact, the low gold content of China's new special drugs can not be ignored, and the reasons include many aspects. According to industry insiders, the development of a new drug in developed countries can be as low as $100 million, and as much as $1 billion. Once the new drug is successfully listed, its annual sales in the world can be as high as $5 billion or more; and in addition to the API market in China's pharmaceutical market, Outside of the international market, pharmaceutical preparations have been blocked. This has resulted in less annual sales of drugs with a level of more than RMB 100 million. The company's sales are not large enough, so it is impossible to invest huge R&D funds. On the other hand, China has 50 - There are relatively few large-scale pharmaceutical enterprises with a total value of 10 billion yuan, and even fewer mega-enterprises with a total value of more than 20 billion yuan. Enterprises lack sufficient pre-research and development funds.
Under this situation, in addition to increasing investment in new special drugs, government departments have encouraged the restructuring of products based on innovative drugs to become an important goal of the "12th Five-Year Plan" for China's biomedical industry. An authoritative source involved in the compilation of the "12th Five-Year Plan" for pharmaceuticals told reporters that during the "12th Five-Year Plan" period, China's pharmaceutical product structure will be adjusted from the "basic drug-based" transition to "mainly based on generic drugs." Ultimately, the model of "based on innovative drugs" will be achieved.
According to the authoritative sources, during the 12th Five-Year Plan period, major new drug creation projects will strive to independently create 30 innovative drugs, complete the transformation and re-innovation of about 200 major drug varieties, and at the same time basically establish a world-class drug innovation system. Cultivate a batch of new drug incubation bases, production and research alliances, and high-tech parks, focusing on breaking through 20-30 key technologies for new drug R&D and industrialization.
2.3 After fermentation Orange (Orange made enzyme solution navel orange), seized after the hand, breaking and other processes made of navel orange sauce.
Effects: lung, spleen shun gas, without any food additives, preservatives, is the first choice of children and senior citizens.
Companies registered capital of 35 million yuan, the end of 2014 the total assets of 48.69 million yuan, including fixed assets of 37.52 million yuan. The company's existing cooperation Orange cultivation base 7043.5 acres, the company production base is located in Jiangxi County Tech Industrial Park Chu Tan industrial area, covers an area of 120 acres, it has built a standard plant 9,000 square meters, Nissan 6000 kg Orange enzymes and other liquid enzyme products. Enzyme, known as enzyme, refers to a polymer substance having biocatalytic functionality. In the catalytic reaction system an enzyme, the reactant molecules are known as substrates, enzyme substrates by catalytic conversion to another molecule. Almost all cellular activity of enzymes involved in the process are required to improve efficiency. Similar to other non-biological catalysts, enzymes chemical reactions by lowering the activation energy to accelerate the rate of the reaction, most of the enzyme catalyzed reaction rate can be increased a million times; in fact, the enzyme is to provide an activation energy needs than another low way, so that more particles to have less than the activation energy of the reaction kinetic energy, thus speeding up the reaction rate. Enzyme as a catalyst, in itself is not consumed during the reaction, it does not affect the chemical equilibrium reactions. Positive enzyme catalysis, but also a negative catalytic effect, not only to accelerate the reaction rate, but also to reduce the reaction rate. And other non-living catalysts is different, having a high degree of specificity of enzyme, only a catalytic reaction or produce a particular specific configuration.
Enzyme Cream,Whitening Slimming Enzyme Cream ,Meal Replacement Diet Enzyme Cream ,Conditioning After Surgery Enzyme Cream
Ganzhou Green days Biochemical Technology Co., Ltd. , http://www.cn-gangdao.com